FDA CBD group leader departs

Share this:

The leader of the U.S. Food & Drug Administration’s CBD Working Group is leaving the agency, FDA Acting Director Janet Woodcock announced this week. Amy Abernethy, FDA’s Principal Deputy Commissioner and Acting Chief Information Officer, joined the agency in 2019, and was named to head the CBD initiative that same year.

Get Hemp Industry Updates

* indicates required

Newsletter Signup

Subscribe to our FREE email newsletter & get the latest hemp industry news directly in your inbox.

* indicates required
Scroll to Top